Low dose interferon-α2b combined with PUVA is an effective treatment of early stage mycosis fungoides: Results of a multicenter study

Haematologica

Volumn 84, Issue 9, 1999, Pages 809-813

  Rupoli, Serena ^a   Barulli, Sara ^b   Guiducci, Barbara ^b   Offidani, Massimo ^b   Mozzicafreddo, Giorgio ^b   Simonacci, Marco ^b   Filosa, Giorgio ^b   Giacchetti, Alfredo ^b   Ricotti, Giuseppe ^b   Brandozzi, Giuliano ^b   Cataldi, Ivana ^b   Serresi, Stefano ^b   Ceschini, Raffaella ^b   Bugatti, Leonardo ^b   Offidani, Anna Maria ^b   Giangiacomi, Mirella ^b   Brancorsini, Donatella ^b   Leoni, Pietro ^b  

^a Clin Ematologia Osp Gen R   (Italy)

^b NONE

Author keywords

Early stages; Interferon 2b; Mycosis fungoides; PUVA

Indexed keywords

ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MYCOSIS FUNGOIDES; PHOTOCHEMOTHERAPY; PUVA; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROSPECTIVE STUDIES; PUVA THERAPY; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0242673060     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Zackeim HS. Treatment of cutaneous T-cell lymphoma. Semin Dermatol 1994; 13:207-15.
2. Bunn PA, Hoffmann SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994; 121:592-602.
3. Ross C, Tingsgaard P, Jorgensen H, et al. Interferon treatment of cutaneous T-cell lymphoma. Eur Haematol 1993; 51:63-7.
4. Roenigk HH, Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95:198S-205S.
5. Mostow EN, Neckel LS, Oberhelman L. Complete remission in psoralen and UV-A (PUVA)-refractory mycosis fungoides type cutaneous T-cell lymphoma with combined interferon-α and PUVA. Arch Dermatol 1993; 129:747-52.
6. Kuzel TM, Roeknigk HH, Samuelson E, et al. Effectiveness of interferon alpha-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995; 13:257-63.
7. Burg G, Renhard D, Kerl H. Classification of cutaneous lymphomas. Dermatol Clin 1994; 12:213-7.
8. Dixon DO, McLaughlin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 1987; 5:1670-2.
9. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-582.
10. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1031-56.
11. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential, and topical mechlorethamine chemoterapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20:416-28.
12. Kuten A, Rosenblatt E, Dale J, et al. Total skin electron irradiation efficacy in early mycosis fungoides. Leuk Lymphoma 1992; 10:281-5.
13. Molin L, Thomsen K, Volden G, et al. Photochemotherapy (PUVA) in the pretumor stage of mycosis fungoides: a report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol 1980; 61: 47-51.
14. Honigsmann H, Brenner W, Rauschhhmeier W, et al. Photochemotherapy for cutaneous T-cell lymphoma. A follow-up study. J Am Acad Dermatol 1984; 11(4 Pt 2):731-5.
15. Abel EA, Sendagorta E, Hoppe RT, et al. PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Arch Dermatol 1987; 123:897-901.
16. Muche MJ, Lukowsky A, Asadullah K, et al. Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood 1997; 90:1636-42.
17. Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon-α-2b and retinoids. J Am Acad Dermatol 1991; 24:247-52.
18. Dreno B, Celerier P, Litoux P. Roferon-A in combination with tigason in cutaneous T-cell lymphomas. Acta Hematol 1993; 89:28-32.
19. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicentric clinical trial on the use of interferon α-2a plus acitretin versus interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92:3578-81.
20. Anderson JR, Propert KJ, Harrington DP. Guidelines for reporting outcomes of lymphoma trials. J Clin Oncol 1988; 6:559-60.
21. Zackheim HS, Mohammed K-S, Hwang ST. Low dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. Am Acad Dermatol 1996; 34:626-31.
22. Demierre MF, Foss F, Koh H. Proceedings of the international consensus conference on cutaneous T-cell lymphoma (CTCL) treatment recommendations. Am Acad Dermatol 1997; 36:460-6.
23. Sterry W, Mielke V. CD4+ cutaneous T-cell lymphomas show the phenotype of helper/inducer T cells (CD45RA-, Cdw29). J Invest Dermatol 1989; 93:413-6.
24. Rook AH, Vowels BR, Jaworsky C, et al. The immunopathogenesis of cutaneous T-cell lymphoma. Arch Dermatol 1993; 129:486-9.
25. Hansen ER. Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma. Arch Dermatol 1996; 132:554-61.